EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm

Renuka Iyer, Laura Kulik, Benjamin Spieler, Anne Noonan, Sarah B. White, Robert J. Lewandowski, Christopher Malone, Jonathan Lindquist, Ahmed Zakari, D. Chimene Richa, James C. F. Schmidt, Priyanka Gogna und 2 weitere

Cancers · 10.11.2026 · 18 (22) · 3598

DOI: 10.3390/cancers18223598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 10.11.2026. Verfasst von Renuka Iyer und 13 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: EMERALD-Y90 (NCT06040099) is a phase II, open-label, single-arm study evaluating Y90 transarterial radioembolisation (TARE) plus durvalumab and bevacizumab for unresectable hepatocellular carcinoma (uHCC) amenable to TARE, without extrahepatic spread. Interim safety was compared with an EMERALD-1 external comparator arm (ECA).

Methods

Participants received TARE with dosimetry, durvalumab (1500 mg) ≥ 14 days later, then durvalumab (1120 mg) plus bevacizumab (15 mg/kg) every 21 days from ≥ 14 days later. Safety was assessed across treatment intervals. The ECA included EMERALD-1 participants who received transarterial chemoembolisation, durvalumab and bevacizumab, and met EMERALD-Y90 eligibility. Inverse probability of treatment weighting balanced prespecified baseline characteristics before comparisons.

Results

At the 9 January 2026 cut-off, 59 participants received TARE (safety set), 58 received durvalumab and 57 received bevacizumab. Treatment-emergent adverse events (TEAEs) occurred in 58 (98.3%) participants, including Grade 3/4 TEAEs in 30 (50.8%); 53 (89.8%) had treatment-related adverse events (TRAEs); 18 (30.5%) had serious adverse events and 8 died (6 unrelated to treatment). Common TEAEs were gastrointestinal (89.8%), musculoskeletal (54.2%), respiratory (54.2%), skin-related (52.5%), and nervous system-related (50.8%). After weighting, EMERALD-Y90 (N = 58) and EMERALD-1 ECA (N = 45) had balanced baseline characteristics and descriptively similar safety; TRAEs occurred in 52 (86.5%) and 40 (87.5%) participants, respectively.

Conclusions

In this interim safety analysis of EMERALD-Y90, TARE followed by durvalumab and bevacizumab showed an encouraging safety profile, consistent with the known component profiles, without new safety signals versus these profiles. Observed safety was broadly similar to the EMERALD-1 ECA, supporting further investigation of this approach in embolisation-eligible uHCC.

Förderung

  • AstraZeneca

Zitieren

APA

Iyer, R., Kulik, L., Spieler, B., Noonan, A., White, S. B., Lewandowski, R. J., Malone, C., Lindquist, J., Zakari, A., Richa, D. C., Schmidt, J. C. F., Gogna, P., Underwood, D., & Salem, R. (2026). Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm. Cancers, 18(22), 3598. https://doi.org/10.3390/cancers18223598

Vancouver

Iyer R, Kulik L, Spieler B, Noonan A, White SB, Lewandowski RJ, et al. Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm. Cancers. 2026;18(22):3598. doi:10.3390/cancers18223598

BibTeX
@article{Iyer2026,
  author = {Iyer, Renuka and Kulik, Laura and Spieler, Benjamin and Noonan, Anne and White, Sarah B. and Lewandowski, Robert J. and Malone, Christopher and Lindquist, Jonathan and Zakari, Ahmed and Richa, D. Chimene and Schmidt, James C. F. and Gogna, Priyanka and Underwood, Dex and Salem, Riad},
  title = {Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3598},
  doi = {10.3390/cancers18223598}
}
Kostenlos starten →